Cargando…

Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins

BACKGROUND: Despite being a mainstay for treating superficial bladder carcinoma and a promising agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains poorly understood. It is particularly unclear whether BCG is capable of altering gene expression beyond its...

Descripción completa

Detalles Bibliográficos
Autores principales: Saban, Marcia R, Hellmich, Helen L, Simpson, Cindy, Davis, Carole A, Lang, Mark L, Ihnat, Michael A, O'Donnell, Michael A, Wu, Xue-Ru, Saban, Ricardo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212656/
https://www.ncbi.nlm.nih.gov/pubmed/17980030
http://dx.doi.org/10.1186/1471-2407-7-204
_version_ 1782148738401173504
author Saban, Marcia R
Hellmich, Helen L
Simpson, Cindy
Davis, Carole A
Lang, Mark L
Ihnat, Michael A
O'Donnell, Michael A
Wu, Xue-Ru
Saban, Ricardo
author_facet Saban, Marcia R
Hellmich, Helen L
Simpson, Cindy
Davis, Carole A
Lang, Mark L
Ihnat, Michael A
O'Donnell, Michael A
Wu, Xue-Ru
Saban, Ricardo
author_sort Saban, Marcia R
collection PubMed
description BACKGROUND: Despite being a mainstay for treating superficial bladder carcinoma and a promising agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains poorly understood. It is particularly unclear whether BCG is capable of altering gene expression beyond its well-recognized pro-inflammatory effects and how this relates to its therapeutic efficacy. The objective of this study was to determine differentially expressed genes in the mouse bladder following repeated intravesical BCG therapy. METHODS: Mice were transurethrally instilled with BCG or pyrogen-free on days 1, 7, 14, and 21. Seven days after the last instillation, urothelia along with the submucosa was removed and amplified ds-DNA was prepared from control- and BCG-treated bladder mucosa and used to generate suppression subtractive hybridization (SSH). Plasmids from control- and BCG-specific differentially expressed clones and confirmed by Virtual Northern were then purified and the inserts were sequenced and annotated. Finally, chromatin immune precipitation combined with real-time polymerase chain reaction assay (ChIP/Q-PCR) was used to validate SSH-selected transcripts. RESULTS: Repeated intravesical BCG treatment induced an up regulation of genes associated with antigen presentation (B2M, HLA-A, HLA-DQA1, HLA-DQB2, HLA-E, HLA-G, IGHG, and IGH) and representatives of two IFNγ-induced small GTPase families: the GBPs (GBP1, GBP2, and GBP5) and the p47GTPases (IIGTP1, IIGTP2, and TGTP). Genes expressed in saline-treated bladders but down-regulated by BCG included: the single-spanning uroplakins (UPK3a and UPK2), SPRR2G, GSTM5, and RSP 19. CONCLUSION: Here we introduced a hypothesis-generator approach to determine key genes involved in the urothelium/sumbmucosa responses to BCG therapy. Urinary bladder responds to repeated BCG treatment by up-regulating not only antigen presentation-related genes, but also GBP and p47 small GTPases, both potentially serving to mount a resistance to the replication of the Mycobacterium. It will be of tremendous future interest to determine whether these immune response cascades play a role in the anti-cancer effects exerted by BCG.
format Text
id pubmed-2212656
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22126562008-01-24 Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins Saban, Marcia R Hellmich, Helen L Simpson, Cindy Davis, Carole A Lang, Mark L Ihnat, Michael A O'Donnell, Michael A Wu, Xue-Ru Saban, Ricardo BMC Cancer Research Article BACKGROUND: Despite being a mainstay for treating superficial bladder carcinoma and a promising agent for interstitial cystitis, the precise mechanism of Bacillus Calmette-Guerin (BCG) remains poorly understood. It is particularly unclear whether BCG is capable of altering gene expression beyond its well-recognized pro-inflammatory effects and how this relates to its therapeutic efficacy. The objective of this study was to determine differentially expressed genes in the mouse bladder following repeated intravesical BCG therapy. METHODS: Mice were transurethrally instilled with BCG or pyrogen-free on days 1, 7, 14, and 21. Seven days after the last instillation, urothelia along with the submucosa was removed and amplified ds-DNA was prepared from control- and BCG-treated bladder mucosa and used to generate suppression subtractive hybridization (SSH). Plasmids from control- and BCG-specific differentially expressed clones and confirmed by Virtual Northern were then purified and the inserts were sequenced and annotated. Finally, chromatin immune precipitation combined with real-time polymerase chain reaction assay (ChIP/Q-PCR) was used to validate SSH-selected transcripts. RESULTS: Repeated intravesical BCG treatment induced an up regulation of genes associated with antigen presentation (B2M, HLA-A, HLA-DQA1, HLA-DQB2, HLA-E, HLA-G, IGHG, and IGH) and representatives of two IFNγ-induced small GTPase families: the GBPs (GBP1, GBP2, and GBP5) and the p47GTPases (IIGTP1, IIGTP2, and TGTP). Genes expressed in saline-treated bladders but down-regulated by BCG included: the single-spanning uroplakins (UPK3a and UPK2), SPRR2G, GSTM5, and RSP 19. CONCLUSION: Here we introduced a hypothesis-generator approach to determine key genes involved in the urothelium/sumbmucosa responses to BCG therapy. Urinary bladder responds to repeated BCG treatment by up-regulating not only antigen presentation-related genes, but also GBP and p47 small GTPases, both potentially serving to mount a resistance to the replication of the Mycobacterium. It will be of tremendous future interest to determine whether these immune response cascades play a role in the anti-cancer effects exerted by BCG. BioMed Central 2007-11-02 /pmc/articles/PMC2212656/ /pubmed/17980030 http://dx.doi.org/10.1186/1471-2407-7-204 Text en Copyright © 2007 Saban et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Saban, Marcia R
Hellmich, Helen L
Simpson, Cindy
Davis, Carole A
Lang, Mark L
Ihnat, Michael A
O'Donnell, Michael A
Wu, Xue-Ru
Saban, Ricardo
Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
title Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
title_full Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
title_fullStr Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
title_full_unstemmed Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
title_short Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
title_sort repeated bcg treatment of mouse bladder selectively stimulates small gtpases and hla antigens and inhibits single-spanning uroplakins
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212656/
https://www.ncbi.nlm.nih.gov/pubmed/17980030
http://dx.doi.org/10.1186/1471-2407-7-204
work_keys_str_mv AT sabanmarciar repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT hellmichhelenl repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT simpsoncindy repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT daviscarolea repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT langmarkl repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT ihnatmichaela repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT odonnellmichaela repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT wuxueru repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins
AT sabanricardo repeatedbcgtreatmentofmousebladderselectivelystimulatessmallgtpasesandhlaantigensandinhibitssinglespanninguroplakins